Trials / Completed
CompletedNCT00488189
Study Evaluation Tazocin Intervention
Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 134 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an antibiotic intervention study to determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tazocin (pipercillin/tazobactam) | over 50% third generation cephalosporin should be replaced by Pip/Taz |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-06-20
- Last updated
- 2011-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00488189. Inclusion in this directory is not an endorsement.